Could less radiation be better? new trial aims to reduce side effects for advanced nose cancer patients
NCT ID NCT07188584
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether giving less radiation to low-risk areas (reduced-target) is as effective as standard full-target radiation for patients with metastatic nasopharyngeal carcinoma who have already responded to chemotherapy and immunotherapy. The study involves 166 adults aged 18-70. The goal is to see if the reduced approach can maintain cancer control while causing fewer serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radiotherapy (reduced-target vs full-target)
- What this could lead to
- If successful, this could establish a new standard of care that reduces radiation side effects while maintaining cancer control for patients with metastatic nasopharyngeal carcinoma.
- What could go wrong
- This is a non-inferiority trial, so it may show that reduced-target radiotherapy is not as effective as the full-target approach. The study is also relatively small (166 participants) and focuses on a specific cancer type.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000 Recruiting
RECRUITINGZhuhai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could avoiding Pre-Radiation tooth removal protect jaw health?
- Can a blood test and MRI tailor cancer therapy to each patient?
- Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
- Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
- Can tumor genetics predict survival in nasopharyngeal cancer?
- Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer